rs3758524 — LTBR LTBR regulatory variant

Intronic regulatory variant near the lymphotoxin beta receptor gene influencing LTBR expression and alternative NF-κB-driven immune signaling

See your personal result for LTBR

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

LTBR Regulatory Variant — Gating the Alternative NF-κB Pathway

The lymphotoxin beta receptor (LTBR)11 lymphotoxin beta receptor (LTBR)
A member of the TNF receptor superfamily encoded on chromosome 12p13.31; binds lymphotoxin-α1β2 and the LIGHT cytokine is a critical organizer of secondary lymphoid tissue architecture and innate immune tone. rs3758524 is a regulatory intronic variant associated with altered LTBR expression. Carriers of the minor A allele may have reduced LTBR signaling output — a change with consequences for how the immune system organizes lymphoid structures and mounts defenses against intracellular pathogens.

The A allele is rare across all populations, occurring in roughly 1–5% of individuals globally, with higher frequencies observed in East Asian populations (approximately 2–5%) compared to Europeans (~1%) or Africans (~1%). Most people carry the common GG genotype.

The Mechanism

LTBR sits at the hub of a dual NF-κB signaling network. When bound by its ligands, LTBR engages the classical IKKβ/IKKγ complex22 When bound by its ligands, LTBR engages the classical IKKβ/IKKγ complex
This leads to rapid degradation of IκBα and transient activation of RelA:p50 dimers, producing an acute inflammatory response. In parallel, LTBR triggers the alternative (non-canonical) NF-κB pathway33 alternative (non-canonical) NF-κB pathway
This pathway uses NIK (NF-κB-inducing kinase) and IKKα to process p100 into p52, generating sustained RelB:p52 complexes that drive lymphoid organogenic genes. These two pathways operate independently and are not redundant — together, they shape chemokine gradients, follicular dendritic cell maturation, and stromal cell function in lymph nodes and spleen.

Regulatory variants that reduce LTBR expression dampen both arms of this response44 Regulatory variants that reduce LTBR expression dampen both arms of this response
Reduced surface receptor density means less signal transduction per ligand-binding event, blunting both the acute RelA response and the sustained RelB organogenic response. The net effect is subtly impaired lymphoid tissue organization and reduced innate capacity to respond to certain pathogens.

The Evidence

LTBR's role in infection defense is most directly established in mycobacterial models. Blocking LTβR signaling in mice infected with Mycobacterium bovis BCG impaired granuloma formation in the spleen, suppressed macrophage activation, reduced nitric oxide synthase activity, and shifted immune responses from Th1 (IFN-γ) to Th2 (IL-4)55 Blocking LTβR signaling in mice infected with Mycobacterium bovis BCG impaired granuloma formation in the spleen, suppressed macrophage activation, reduced nitric oxide synthase activity, and shifted immune responses from Th1 (IFN-γ) to Th2 (IL-4)
A soluble LTβR-IgG1 fusion protein was used to block signaling. Critically, the LTBR and TNF receptor pathways are non-redundant66 non-redundant
Blocking both simultaneously caused extensive splenic necrosis — neither compensates for the other.

For the specific rsid, direct human genetic association data is limited. However, the broader LTBR variant literature provides biological grounding. A study of LTBR rs12354 in hepatitis B found that the T allele was significantly enriched in HBV spontaneous resolvers77 A study of LTBR rs12354 in hepatitis B found that the T allele was significantly enriched in HBV spontaneous resolvers
GT genotype: 38.4% in resolvers vs 22.2% in chronically infected patients (p = 0.004), suggesting that genetic differences in LTBR function modulate viral infection outcomes. LTBR promoter variants (rs3759334 and rs2364480) were associated with IgA nephropathy in Korean children88 LTBR promoter variants (rs3759334 and rs2364480) were associated with IgA nephropathy in Korean children
rs3759334 dominant model p = 0.017; rs2364480 allele p = 0.041, implicating LTBR in immune-complex-mediated inflammatory disease susceptibility.

In the context of juvenile idiopathic arthritis and systemic sclerosis, LTBR pathway activity influences tertiary lymphoid structure (TLS) formation at inflamed joints and fibrotic tissues — a mechanism under active investigation. The evidence base for rs3758524 specifically is emerging, with no large-scale genetic association studies published to date.

Practical Implications

Carriers of the A allele face a modestly altered baseline of LTBR-mediated immune signaling. The main practical concerns are in two areas: susceptibility to certain intracellular pathogens that rely on granuloma-mediated containment, and potentially altered risk of inflammatory conditions where tertiary lymphoid structures shape disease chronicity. Given the rarity of the A allele and the emerging state of the evidence, the actionable focus is on monitoring and early intervention for infections rather than any specific preventive supplement or avoidance.

Interactions

LTBR signaling interacts functionally with the TNF receptor pathway (TNFR1/TNFR2), and these pathways show additive rather than redundant effects in controlling intracellular infections. LTBR-driven alternative NF-κB also intersects with LIGHT/HVEM signaling (TNFRSF14, rs1886730), which shares ligands and downstream targets. Variants in the classical NF-κB arm (RELA, NFKB1) could modulate how much compensation occurs when LTBR signaling is reduced.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal LTBR Signaling Normal

Standard lymphotoxin beta receptor function with normal NF-κB activation and immune organization

You carry two copies of the common reference allele at this LTBR regulatory site. The vast majority of people — roughly 96% globally — share this genotype. Your LTBR signaling operates at typical levels, supporting normal secondary lymphoid organ development, conventional granuloma formation against intracellular pathogens, and balanced alternative NF-κB activity.

AG Reduced LTBR Expression Intermediate

One copy of the regulatory variant associated with moderately reduced LTBR signaling capacity

LTBR drives both acute (RelA:p50) and sustained (RelB:p52) NF-κB responses. With one functional regulatory variant, the absolute signal may be sufficient for most immune challenges, but under conditions of high pathogen burden or immune stress — such as chronic infection or concurrent autoimmune inflammation — the reduced reserve could matter. The heterozygous state is common enough that its effect is likely modest.

In the broader context of LTBR biology, variants affecting expression have been linked to altered susceptibility to viral infections (HBV clearance) and immune-complex kidney disease. For JIA and systemic sclerosis, LTBR-dependent tertiary lymphoid structure formation may influence whether inflammation becomes self-sustaining — a mechanism where even modest signaling reductions could be relevant over years of chronic disease.

AA Homozygous Variant High Risk

Both copies carry the regulatory variant, associated with the most reduced LTBR signaling capacity

With both regulatory copies carrying the A variant, LTBR surface density may be substantially reduced. In mouse models, complete LTBR pathway blockade impairs spleen granuloma formation, drives macrophage nitric oxide suppression, and shifts immune responses from protective Th1 (IFN-γ dominant) toward Th2 (IL-4 dominant). This immune skew creates vulnerability to pathogens that normally require Th1-driven granulomas for long-term containment.

The alternative NF-κB arm (NIK→IKKα→RelB:p52) is particularly affected. This arm drives organogenic chemokines essential for follicular dendritic cell maturation and lymph node architecture. Reduced RelB:p52 activity can impair the formation and maintenance of tertiary lymphoid structures in chronically inflamed tissues, relevant to JIA joint inflammation and scleroderma lung disease where such structures drive adaptive immune amplification.

Given the extreme rarity of homozygous AA genotype, direct clinical data are not available for this genotype specifically; the evidence is extrapolated from heterozygous carrier studies and animal model data.